Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer

[1]  D. Cunningham,et al.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Santosh Shenoy.  CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management , 2019, Cancer management and research.

[3]  J. Ajani,et al.  Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer , 2019, Journal of surgical oncology.

[4]  R. van Hillegersberg,et al.  Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer—A Systematic Review , 2019, Journal of Clinical Medicine.

[5]  T. Fukagawa.  Role of staging laparoscopy for gastric cancer patients , 2019, Annals of gastroenterological surgery.

[6]  R. Salazar,et al.  Comparison and applicability of molecular classifications for gastric cancer. , 2019, Cancer treatment reviews.

[7]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  M. Egger,et al.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.

[9]  D. Park,et al.  Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial , 2019, JAMA oncology.

[10]  S. Rausei,et al.  Conversion surgery for gastric cancer patients: A review , 2018, World journal of gastrointestinal oncology.

[11]  A. Spaziani,et al.  Oncologic Effectiveness and Safety of Bursectomy in Patients with Advanced Gastric Cancer: A Systematic Review and Updated Meta-Analysis , 2018, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[12]  N. Pantazis,et al.  Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors , 2018, Annals of gastroenterology.

[13]  T. Yoshikawa,et al.  Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. , 2018, The lancet. Gastroenterology & hepatology.

[14]  A. Gardini,et al.  Conversion surgery for gastric cancer: A cohort study from a western center. , 2018, International journal of surgery.

[15]  H. Putter,et al.  Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[16]  R. Reddavid,et al.  Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? , 2018, World journal of gastroenterology.

[17]  A. Batistatou,et al.  The first report of a 5-year period cancer registry in Greece (2009–2013): a pathology-based cancer registry , 2018, Virchows Archiv.

[18]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[19]  J. Meyerhardt,et al.  Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Song Liu,et al.  Whole-lesion apparent diffusion coefficient histogram analysis: significance in T and N staging of gastric cancers , 2017, BMC Cancer.

[21]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[22]  J. Ajani,et al.  Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project , 2017, Clinical Cancer Research.

[23]  V. Gebski,et al.  TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG , 2017, Annals of Surgical Oncology.

[24]  Zhen-ning Wang,et al.  The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature , 2017, World Journal of Surgical Oncology.

[25]  Y. Soon,et al.  Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis , 2017, Oncotarget.

[26]  T. Yoshikawa,et al.  Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma , 2017, Annals of surgery.

[27]  M. Nilsson.  Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice , 2016, Gastric Cancer.

[28]  F. Smedts,et al.  Role of omentectomy as part of radical surgery for gastric cancer , 2016, The British journal of surgery.

[29]  Zhen Zhang,et al.  Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis , 2016, World Journal of Surgical Oncology.

[30]  H. Kang,et al.  Understanding the diagnostic yield of current endoscopic biopsy for gastric neoplasm , 2016, Medicine.

[31]  S. Maithel,et al.  The importance of surgical margins in gastric cancer , 2016, Journal of surgical oncology.

[32]  R. van Hillegersberg,et al.  The Oncological Value of Omentectomy in Gastrectomy for Cancer , 2016, Journal of Gastrointestinal Surgery.

[33]  B. O'Sullivan,et al.  UICC Manual of Clinical Oncology: O'Sullivan/UICC , 2015 .

[34]  K. Muro,et al.  Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study , 2015, BMC Palliative Care.

[35]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[36]  Y. Doki,et al.  Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial. , 2015, Surgery.

[37]  Joon-Oh Park,et al.  Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Shin,et al.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[39]  M. Ychou,et al.  Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[41]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[42]  A. Hölscher,et al.  Treatment of early gastric cancer in the Western World. , 2014, World journal of gastroenterology.

[43]  V. Lemmens,et al.  Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors , 2014, International journal of cancer.

[44]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[45]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  V. Goh,et al.  Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Y. Doki,et al.  Comparison of Billroth I and Roux-en-Y Reconstruction after Distal Gastrectomy for Gastric Cancer: One-year Postoperative Effects Assessed by a Multi-institutional RCT , 2013, Annals of surgical oncology.

[48]  A. Meloni-Ehrig,et al.  Gastric cancer: Classification, histology and application of molecular pathology. , 2012, Journal of gastrointestinal oncology.

[49]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Rinku Sutradhar,et al.  How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis , 2012, Gastric Cancer.

[51]  J. Ajani,et al.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Sang-Hoon Ahn,et al.  What is the best reconstruction method after distal gastrectomy for gastric cancer? , 2012, Surgical Endoscopy.

[53]  D. Jong,et al.  Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance , 2012, Familial Cancer.

[54]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[55]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[58]  J. Pignon,et al.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Tonsok Kim,et al.  Preoperative T staging of gastric cancer by multi-detector row computed tomography. , 2011, Surgery.

[60]  K. Okada,et al.  Endoscopic ultrasonography is valuable for identifying early gastric cancers meeting expanded-indication criteria for endoscopic submucosal dissection , 2011, Surgical Endoscopy.

[61]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[62]  S. Choo,et al.  Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. , 2010, World journal of gastroenterology.

[63]  C. Caldas,et al.  Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research , 2010, Journal of Medical Genetics.

[64]  Jae Young Lee,et al.  Diagnostic performance of 64-channel multidetector CT in the evaluation of gastric cancer: differentiation of mucosal cancer (T1a) from submucosal involvement (T1b and T2). , 2010, Radiology.

[65]  H. Putter,et al.  Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Yasuo Ohashi,et al.  Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer , 2009 .

[67]  P. Rosenberg,et al.  Age-specific trends in incidence of noncardia gastric cancer in US adults. , 2010, JAMA.

[68]  Michihiko Shibata,et al.  Gastric mucosal cancer smaller than 7mm can be treated with conventional endoscopic mucosal resection as effectively as with endoscopic submucosal dissection. , 2010, Hepato-gastroenterology.

[69]  H. Putter,et al.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. , 2010, The Lancet. Oncology.

[70]  M. Feith,et al.  Pouch vs. No Pouch Following Total Gastrectomy: Meta-Analysis and Systematic Review , 2009, The American Journal of Gastroenterology.

[71]  A. Tan,et al.  Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract , 2009, Endoscopy.

[72]  F. Kondo,et al.  Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. , 2009, Endoscopy.

[73]  N. Yahagi,et al.  Benefits of endoscopic submucosal dissection according to size and location of gastric neoplasm, compared with conventional mucosal resection , 2009, Journal of gastroenterology and hepatology.

[74]  L. Chang,et al.  The role of staging laparoscopy for intraabdominal cancers: an evidence-based review , 2009, Surgical Endoscopy.

[75]  Y. Wang,et al.  An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[76]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[77]  F. Schmidt.  Meta-Analysis , 2008 .

[78]  H. Bartelink,et al.  A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. , 2007, International journal of radiation oncology, biology, physics.

[79]  B. Fernandez,et al.  Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. , 2007, JAMA.

[80]  R. Jeffrey,et al.  CDH1 Truncating Mutations in the E-Cadherin Gene: An Indication for Total Gastrectomy to Treat Hereditary Diffuse Gastric Cancer , 2007, Annals of surgery.

[81]  Laura H. Tang,et al.  Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer , 2007, Annals of Surgical Oncology.

[82]  H. Inoue,et al.  A multicenter retrospective study of endoscopic resection for early gastric cancer , 2006, Gastric Cancer.

[83]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Ajani,et al.  Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[86]  H. Chung,et al.  Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer , 2006, The British journal of surgery.

[87]  J. Mari,et al.  Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[88]  N. Talley,et al.  Guidelines for the Management of Dyspepsia , 2005, The American Journal of Gastroenterology.

[89]  Hong Nguyen,et al.  Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. , 2004, Archives of pathology & laboratory medicine.

[90]  Masao Ichinose,et al.  Endoscopic submucosal dissection for early gastric cancer using the tip of an electrosurgical snare (thin type) , 2004 .

[91]  C Caldas,et al.  Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. , 2001, Gastroenterology.

[92]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[93]  George Wright,et al.  The Delphi technique as a forecasting tool: issues and analysis , 1999 .

[94]  A. Hölscher,et al.  Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. , 1999, AJR. American journal of roentgenology.

[95]  Colin-Jones Dg,et al.  Guidelines for the management of dyspepsia. , 1999 .

[96]  M. Tada,et al.  Endoscopic and histologic diagnosis of submucosal tumors of the gastrointestinal tract using combined strip biopsy and bite biopsy. , 1994, Gastrointestinal endoscopy.

[97]  A. Zauber,et al.  Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. , 1991, Radiology.

[98]  C. McConkey,et al.  Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. , 1990, British Journal of Cancer.

[99]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[100]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[101]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[102]  David M. Kuehn,et al.  MDCT imaging of the stomach: advances and applications. , 2017, The British journal of radiology.

[103]  ESMO Guidelines Committee. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  Y. Kodera,et al.  Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference , 2015, Gastric Cancer.

[105]  B. O'Sullivan.  UICC manual of clinical oncology , 2015 .

[106]  D. Cunningham,et al.  Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[107]  T. Hashimoto,et al.  Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? , 2010, Journal of Cancer Research and Clinical Oncology.

[108]  J. Ajani,et al.  Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group , 2006 .

[109]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.